Cytotoxic T Lymphocyte Antigen 4 (ctla 4) - Cancer Science

Relevant Publications

Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets.

Issue Release: 2024

Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease.

Issue Release: 2024

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).

Issue Release: 2024

Blocking CTLA-4 promotes pressure overload-induced heart failure via activating Th17 cells.

Issue Release: 2024

Recent advances in immunotherapy in cancer treatment.

Issue Release: 2024

Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers.

Issue Release: 2024

Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibitors for Advanced or Metastatic Non-Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials.

Issue Release: 2024

Current research insights into the role of CTLA-4 in hepatitis B virus (HBV) infection.

Issue Release: 2024

Immune checkpoint inhibitors: breakthroughs in cancer treatment.

Issue Release: 2024

Inhibition of interferon regulatory factor 4 orchestrates T cell dysfunction, extending mouse cardiac allograft survival.

Issue Release: 2024

Cholesterol and Immune Microenvironment: Path Towards Tumorigenesis.

Issue Release: 2024

Differences in IDO1 dendritic cells and soluble CTLA-4 are associated with differential clinical responses to methotrexate treatment in rheumatoid arthritis.

Issue Release: 2024

Cornus Officinalis Total Glycosides Alleviate Granulomatous Lobular Mastitis via the B7-CD28/CTLA-4 Costimulatory Pathway.

Issue Release: 2024

[Immune mechanism of Daphnes Cortex and its processed products on CIA rats based on B7/CD28/CTLA-4 pathway].

Issue Release: 2024

Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab.

Issue Release: 2024

Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors.

Issue Release: 2024

The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers.

Issue Release: 2024

Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.

Issue Release: 2024

Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) gene polymorphisms in a cohort of Egyptian patients with immune thrombocytopenia (ITP).

Issue Release: 2024

Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.

Issue Release: 2024

What role do biomarkers play in cancer treatment?

How Do Blister Packs Benefit Cancer Patients?

How to Prepare for Bone Marrow Aspiration?

What are the Benefits of Telemedicine in Cancer Care?

Which Types of Cancer Are Most Commonly Associated with Dysphagia?

How do Keratins Affect Tumor Behavior?

Which Cancers are Associated with MSI-H?

What are the Challenges in Using Natural Compounds for Cancer Treatment?

How is Processed Meat Linked to Cancer?

Why is Tumor Location Important in Cancer?

Cytotoxic T Lymphocyte Antigen 4 (ctla 4) - Cancer Science

Relevant Publications

Partnered Content Networks

Relevant Topics